Etid klinik pou Leukemi nan Connecticut
11 etid pou Leukemi ap chèche patisipan nan sit nan Connecticut.
Vil nan Connecticut
Tèks ofisyèl etid la (Anglè)
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, New Haven
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- Connecticut Children's Medical Center, Hartford
Ap rekriteEtid obsèvasyon
Jiska laj 30 · Tout sèks · Mizajou Jul 16, 2026 · NCT04968834Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, New Haven
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Yale University, New Haven
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Mar 25, 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT05735184SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.